Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one chemotherapy drug (combination chemotherapy) together with cetuximab may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying three different combination chemotherapy regimens to compare how well they work when given together with cetuximab in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer.


Options:
A: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
B: Arm Label: A1: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm A2: Capecitabine Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Arm A3: MEDI4736 (Durvalumab); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab) | Arm Label: Arm B1: Trastuzumab Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Arm Label: Arm A4: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Arm A5: Capecitabine and Ramucirumab; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ramucirumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A2: Capecitabine Maintenance, Arm A5: Capecitabine and Ramucirumab | Intervention Type: DRUG; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Arm A3: MEDI4736 (Durvalumab) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm B1: Trastuzumab Maintenance | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Arm A4: Rucaparib | Intervention Type: DRUG; Name: Ramucirumab; Assigned to Arm(s): Arm A5: Capecitabine and Ramucirumab
C: Arm Label: Arm A (ECF + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: ECF | Arm Label: Arm B (IC + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: IC | Arm Label: ARM C (FOLFOX + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: FOLFOX | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): ARM C (FOLFOX + cetuximab), Arm A (ECF + cetuximab), Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: ECF; Assigned to Arm(s): Arm A (ECF + cetuximab) | Intervention Type: DRUG; Name: IC; Assigned to Arm(s): Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: FOLFOX; Assigned to Arm(s): ARM C (FOLFOX + cetuximab)
D: Arm Label: Arm A: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib plus capecitabine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Arm A: Lapatinib | Intervention Type: DRUG; Name: Lapatinib plus capecitabine; Assigned to Arm(s): Arm B

Answer: C